MINI LONG - NOVO-NORDISK B | Real-time Bid/Ask 17:12:14 17/06/2024 BST | ||
| 17.98 EUR / 18 EUR | -1.75% |
|
| Current month | +11.44% | ||
| 1 month | +12.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 18.12 | -1.04% |
| 14/06/24 | 18.31 | +0.99% |
| 13/06/24 | 18.13 | +0.11% |
| 12/06/24 | 18.11 | -0.66% |
| 11/06/24 | 18.23 | -0.44% |
Delayed Quote Börse Stuttgart
Last update June 17, 2024 at 03:38 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA8FBQ |
| ISIN | DE000MA8FBQ9 |
| Date issued | 09/08/2021 |
| Strike | 311.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.97 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.32 € |
|---|---|
| Lowest since issue | 0.56 € |
| Spread | 0.02 € |
| Spread % | 0.11% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat